Zai Lab Limited (ZLAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZLAB Stock Price Chart Interactive Chart >
ZLAB Price/Volume Stats
|Current price||$43.68||52-week high||$152.82|
|Prev. close||$45.56||52-week low||$22.51|
|Day high||$45.80||Avg. volume||707,637|
|50-day MA||$37.60||Dividend yield||N/A|
|200-day MA||$49.20||Market Cap||4.28B|
Zai Lab Limited (ZLAB) Company Bio
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics for oncology, and autoimmune and infectious disease therapies in China. The company was founded in 2013 and is based in Shanghai, China.
Most Popular Stories View All
ZLAB Latest News Stream
|Loading, please wait...|
ZLAB Latest Social Stream
View Full ZLAB Social Stream
Latest ZLAB News From Around the Web
Below are the latest news stories about Zai Lab Ltd that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.
In this article we present the list of Top 10 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying. Click to skip ahead and see the Top 5 Healthcare Stocks the Experts at Sphera Global Healthcare Fund Are Buying. Johnson & Johnson (NYSE:JNJ), Merck & Co., Inc. (NYSE:MRK), and Perrigo Co Plc (NASDAQ:PRGO) were […]
Zai Lab (ZLAB) said the Center for Drug Evaluation ((CDE)) of the National Medical Products Administration ((NMPA)) granted breakthrough therapy designation to repotrectinib for…
--- Potential best-in-class therapy for ROS1-positive metastatic NSCLC and advanced solid tumorsSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrectinib for th
-- Company to Host Conference Call and Webcast on March 2, 2022, at 8:00 a.m. ETSHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that it will report financial results and corporate updates for the twelve months ended December 31, 2021, after the closing of the U.S. equity markets on March 1, 2022. The Company will host a
Investment company Quaero Capital S.A. (Current Portfolio) buys Canadian National Railway Co, Cheniere Energy Inc, CenterPoint Energy Inc, Air Products & Chemicals Inc, NICE, sells Futu Holdings, TPI Composites Inc, Zai Lab, Farfetch, NIO Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Quaero Capital S.A..
ZLAB Price Returns